Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program

Celmatix, Inc., the leading women’s health biotechnology company focused on ovarian biology, has announced a breakthrough in its novel oral fertility drug program. The program aims to eliminate follicle stimulating hormone (FSH) injections from in vitro fertilization (IVF) and egg freezing protocols, as well as reduce the need for IVF by improving outcomes with ovulation induction and treating m..